Tweet
Neurologists are excited about this new drug and it may have a more palatable safety profile than Gilenya. - Dave
April 26, 2012 (New Orleans, Louisiana) — Full results of a second phase 3 trial of oral BG-12 (dimethyl fumarate, Biogen Idec) in relapsing-remitting multiple sclerosis (MS) show that the drug significantly reduced annualized relapse rates vs placebo and compared favorably to glatiramer acetate (Copaxone, Teva Pharmaceuticals) in a reference group.
Results of the Comparator and an Oral Fumarate in RRMS (CONFIRM) trial showed that the still-investigational oral drug met the study's primary endpoint, significantly reducing the annualized relapse rate by 44% for the twice-daily (BID) dose and by 51% for the thrice-daily (TID) dose vs placebo at 2 years. Treatment also reduced T1 lesions, T2 lesions, and the risk for relapse, as well as the 12-week confirmed disability progression, although this latter finding was not statistically significant.
http://www.medscape.com/viewarticle/762736
Results of the Comparator and an Oral Fumarate in RRMS (CONFIRM) trial showed that the still-investigational oral drug met the study's primary endpoint, significantly reducing the annualized relapse rate by 44% for the twice-daily (BID) dose and by 51% for the thrice-daily (TID) dose vs placebo at 2 years. Treatment also reduced T1 lesions, T2 lesions, and the risk for relapse, as well as the 12-week confirmed disability progression, although this latter finding was not statistically significant.
http://www.medscape.com/viewarticle/762736